This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Boehringer Ingelheim fined in Romania for lung-drug dominance abuse

( January 13, 2025, 11:28 GMT | Official Statement) -- MLex Summary: Pharmaceutical company Boehringer Ingelheim has been fined more than 128 million lei (around $26.4 million) in Romania, for abusing its dominant position on the market for drugs used to treat chronic obstructive pulmonary disease. The company was found to have limited the market access of Spiriva, a cheaper generic drug, to steer patients toward Spiolto Respimat, a more expensive COPD medication. The conduct lasted from 2017 to 2021, the Romanian antitrust authority said today.Statement follows. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections